Innovative drug Torico for delaying the progression of type 1 diabetes approved in China
September 5, 2025
Source: drugdu
131
On September 3, Sanofiannounced that its Tilizumab Injection (trade name: Terico) has been approved by the China National Medical Products Administration (NMPA) for use in children aged 8 years and above and adults with stage 2 type 1 diabetes to delay progression to stage 3 type 1 diabetes.
https://finance.eastmoney.com/a/202509033503446424.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
